Breaking Down the Magtein Clinical Trial: Magnesium L-Threonate for Cognition and Sleep
Katie Brouwer·Health journalist with a data-first approach. Compares vitamins, minerals, and supplements so you can make informed choices without the marketing noise.··8 min read
Magnesium L-Threonate Cognitive Trial Breakdown: What the Magtein Data Shows
Two well-designed randomised controlled trials published in 2024 and 2026 put Magnesium L-Threonate (sold under the brand name Magtein®) to the test on two outcomes that matter to a lot of people: sharper thinking and better sleep. The results are notable enough to be worth reading carefully, and specific enough that you can make an informed call about whether this supplement fits your situation.
This article walks through each magnesium L-threonate cognitive trial in detail: the designs, the actual numbers, the safety picture, and what the research does and does not tell you.
What Is Magnesium L-Threonate?
Magnesium L-Threonate (abbreviated MgL-T or MgT) is a compound formed by binding magnesium to L-threonic acid, a metabolite of vitamin C. Unlike common magnesium salts such as magnesium oxide or magnesium citrate, the threonate form was specifically engineered to cross the blood-brain barrier more efficiently.
The foundational animal research, published in Neuron in 2010, showed that MgL-T raises magnesium concentrations in cerebrospinal fluid, increases the density of NR2B-containing NMDA receptors at hippocampal and cortical synapses, and boosts the number of presynaptic release sites. In rats, this translated into measurable improvements in both short-term and long-term memory[6]. That preclinical work laid the rationale for moving into human trials.
Why does brain magnesium matter in the first place? Magnesium acts as a cofactor for over 300 enzymatic reactions. In the nervous system specifically, it regulates synaptic plasticity, the process by which synaptic connections strengthen or weaken in response to activity. Low brain magnesium is associated with reduced plasticity and, over time, with impaired memory consolidation. The challenge until MgL-T came along was that standard oral magnesium supplements raise serum levels but do not reliably raise cerebrospinal fluid levels.
It is important to note that the animal data is from 2010 and the mechanism work in humans remains inferential. The clinical trials measure outcomes like memory scores and sleep quality, not direct brain magnesium concentrations in living people.
Who Is Most Likely to Benefit?
The populations studied across the two main trials are adults with self-reported sleep dissatisfaction or cognitive concerns, ranging from 18 to 55 years old. Neither trial targeted people with diagnosed cognitive disorders. One separate small open-label study looked at mild-to-moderate Alzheimer's patients, but that study had no control group and is hypothesis-generating at best.
Frequently Asked Questions
This content is for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any supplement or making changes to your health regimen.
KB
Katie Brouwer
Health journalist with a data-first approach. Compares vitamins, minerals, and supplements so you can make informed choices without the marketing noise.
Health journalist with a data-first approach. Compares vitamins, minerals, and supplements so you can make informed choices without the marketing noise.
magnesiumcognitive-healthsleepclinical-trials
Related Articles
supplements
Clinical Trials
How to Evaluate Health Claims on Supplement Labels
How to evaluate supplement health claims: claim types, third-party certification, red flags, and evidence assessment to make informed choices.
Based on the available trial data, the people most likely to see measurable benefit fall into a few overlapping groups. Adults who report poor sleep quality and wake up feeling unrefreshed are one clear group, given that both trials enrolled participants on the basis of self-reported sleep problems[1][2]. People who notice cognitive slowing, working memory lapses, or slower mental processing, particularly if those issues co-occur with disrupted sleep, match the profile of the Lopresti et al. trial population[1].
Magnesium deficiency is also worth considering. If you are new to the topic, our guide to magnesium forms and absorption covers why different magnesium salts behave so differently in the body. A large systematic review and meta-analysis covering more than 151,000 participants found a U-shaped relationship between serum magnesium and dementia risk, with optimal serum levels around 0.85 mmol/L. Participants below 0.75 mmol/L had a hazard ratio of 1.43 (95% CI 1.05-1.93) for developing dementia[4]. Magnesium deficiency is more common than most people realise, particularly in adults who consume processed food diets, take proton pump inhibitors, or drink alcohol regularly.
Older adults within the studied age ranges appear to show stronger cognitive gains. The Zhang et al. trial found that participants aged 50-65 demonstrated greater improvements in overall memory quotient compared to younger participants[3]. If you are younger and already have adequate magnesium intake and good sleep, the effect size on cognition may be smaller.
What the Clinical Trials Actually Show
The most rigorous data comes from two randomised, double-blind, placebo-controlled trials.
The 2026 Lopresti et al. trial enrolled 100 adults aged 18-45 who reported dissatisfaction with their sleep. Participants received either 2 g/day of Magtein® or placebo for six weeks. On the NIH Toolbox Cognition Battery, the Magtein group showed a statistically significant improvement on the Total Cognition Composite score (p=0.043). Breaking that down by subtest: working memory improved (p=0.033) and reaction time improved (p=0.031). The researchers calculated that these gains corresponded to approximately a 7.5-year reduction in cognitive brain age relative to baseline[1]. That is a striking headline number. It means participants performed as if they were cognitively 7.5 years younger compared to where they started.
The 2024 Hausenblas et al. trial took a shorter protocol: 21 days of MgT at 1 g/day in 80 adults aged 35-55 with self-assessed sleep problems. Objective deep sleep scores improved (p<0.001). REM sleep improved (p=0.020). An activity score improved (p=0.010), and daytime measures including mental alertness (p=0.003) and behaviour upon awakening (p=0.004) both reached significance[2].
A third RCT, Zhang et al. 2022, used a formula combining Magtein® with phosphatidylserine and vitamins C and D in 109 healthy Chinese adults aged 18-65. After 30 days at 2 g/day, all five cognitive subcategories and the overall memory quotient improved versus placebo (p<0.001)[3]. The multi-ingredient formula makes it impossible to attribute the effect to MgL-T alone, which is a meaningful limitation.
A meta-analysis published in Advances in Nutrition in 2024 reviewed three MgT-related RCTs alongside 12 cohort studies covering more than 151,000 participants and concluded that RCT evidence remains insufficient for definitive conclusions about magnesium supplementation and cognitive outcomes[4]. That is an honest read of the landscape: the individual trials are promising, but the evidence base is still small.
One additional caveat applies to all three RCTs discussed here: they were industry-funded. Lopresti et al. was funded by Threotech Inc. and Hausenblas et al. by AIDP Inc. Industry funding does not invalidate findings, but it is a factor to weigh when interpreting effect sizes and conclusions.
The Sleep Evidence: A Closer Look
Sleep outcomes appear across both primary trials, and they are worth examining separately because the mechanisms driving sleep improvements may differ from those driving cognitive gains.
In the Lopresti et al. trial, sleep-related impairment on the PROMIS Sleep-Related Impairment scale improved significantly in the Magtein group (p=0.043). The same trial also found a reduction in resting heart rate (p=0.030) and an increase in heart rate variability (p=0.036) in the Magtein group[1]. Heart rate variability is a marker of autonomic nervous system balance, and higher HRV at rest is generally associated with better recovery and sleep quality.
The Hausenblas et al. trial provides more granular sleep architecture data. Objective deep sleep scores improved with p<0.001, a very strong signal for a 21-day supplement trial[2]. REM sleep also improved, which matters because REM is strongly linked to memory consolidation, emotional regulation, and cognitive restoration. If MgL-T is improving both sleep architecture and cognitive test scores, it raises the question of whether those cognitive gains are partly mediated through better sleep rather than direct neurological effects.
For context, a broader meta-analysis of general oral magnesium supplementation (not MgL-T specific) in older adults found an average reduction in sleep onset latency of 17 minutes versus placebo (95% CI -27.27 to -7.44; p=0.0006)[5]. The evidence quality for that meta-analysis was rated low to very low, and the studies did not use MgL-T. It is included here only to show that the sleep-magnesium connection has some wider support, even if the form-specific data is limited.
Taken together, the sleep data across both trials is directionally consistent: MgL-T at 1-2 g/day appears to improve both subjective sleep experience and objective sleep architecture markers. The trials are short (3-6 weeks), so nothing is known about whether these effects persist, attenuate, or require cycling.
Safety and Side Effects
The safety profile across both trials is reassuring, though the trials are too short and too small to detect rare adverse events.
In Lopresti et al., 10% of the Magtein group reported treatment-related adverse events compared to 8% in the placebo group. The most common events were mild gastrointestinal issues such as loose stools or stomach discomfort. No serious adverse reactions were recorded in either group[1].
Hausenblas et al. reported a more favourable picture: 4 adverse events total in the MgT group versus 13 in the placebo group. None of the adverse events in the MgT group were classified as probable or higher severity[2]. This lower adverse event rate in the treatment arm compared to placebo is an unusual finding and may reflect the short duration and selected population rather than a meaningful protective effect.
Magnesium in general has a well-established safety ceiling set by the tolerable upper intake level for supplemental magnesium: 350 mg of elemental magnesium per day for adults. At 2 g/day of Magtein®, the elemental magnesium content is approximately 144 mg, which sits below that threshold. That said, individuals with kidney disease should be cautious with any magnesium supplement because impaired kidneys cannot excrete excess magnesium efficiently.
There are no documented serious drug interactions specific to MgL-T in the published literature. Magnesium in general can reduce absorption of certain antibiotics (particularly tetracyclines and fluoroquinolones) and some bisphosphonates if taken at the same time. Spacing doses at least two hours apart from those medications is the standard guidance.
Dosing and How to Use It
The two trials used different doses and durations, and both produced statistically significant results. That gives some practical flexibility.
The standard commercial dose of Magtein® is typically three 667 mg capsules per day, which delivers 2 g of the compound and approximately 144 mg of elemental magnesium. Some users split this as two capsules in the evening and one in the morning, reasoning that the sleep-oriented effects are more relevant later in the day. The trials themselves did not specify strict timing protocols, so the optimal split is not established by the data.
For sleep-focused goals, the Hausenblas trial suggests that even 1 g/day for three weeks produces measurable changes in sleep architecture. If your primary interest is cognitive performance, the Lopresti trial used 2 g/day over six weeks and showed the broadest cognitive gains including the 7.5-year cognitive age reduction finding[1].
For a broader look at how to read supplement labels and certifications, see our supplement quality guide. When choosing a product, look for one that specifies Magtein® as the active ingredient. This is the patented form developed by MIT-affiliated researchers and the form used in both primary trials. Generic magnesium threonate products may or may not use the same material and have not been tested in the same way. Third-party testing certification (NSF, USP, Informed Sport) is worth prioritising, particularly if you are in a tested sport or simply want verified label accuracy.
Give the supplement at least three to six weeks before assessing whether it is working. Both significant trials ran for at least 21 days, and the stronger cognitive data came from the six-week protocol.
Frequently Asked Questions
Q. Is Magnesium L-Threonate better than other forms of magnesium for the brain?
The available human RCT data is specific to MgL-T and has not been directly compared to other forms in head-to-head trials on cognitive outcomes. The rationale for preferring MgL-T is its demonstrated ability to raise cerebrospinal fluid magnesium in animal models, which other forms appear to do less efficiently[6]. For general magnesium sufficiency, forms like magnesium glycinate or magnesium malate may be equally effective and are often less expensive.
Q. How long does it take to notice effects?
The Hausenblas trial showed objective sleep architecture improvements within 21 days at 1 g/day[2]. The broader cognitive gains in the Lopresti trial were measured at six weeks[1]. Based on the trial protocols, a fair assessment window is four to six weeks of consistent daily use.
Q. Is Magtein® safe to take long-term?
The trials covered three to six weeks, so long-term data does not exist from RCTs. Given that the elemental magnesium content per day (approximately 144 mg at 2 g Magtein®) falls below the established tolerable upper intake level of 350 mg, the theoretical safety margin is reasonable for most healthy adults. People with kidney disease or those taking medications affected by magnesium absorption should consult a healthcare provider before starting.
Q. Can Magnesium L-Threonate help with Alzheimer's disease?
One small open-label trial in 15 patients with mild to moderate Alzheimer's found MMSE improvements, but there was no control group and the imaging findings did not survive statistical correction[7]. This is very early, low-quality data. MgL-T has not been studied in adequately powered, controlled trials for Alzheimer's disease, so no conclusions about treatment can be drawn from the current evidence.
Q. Does the industry funding of these trials affect how to interpret the results?
Industry funding is a recognised source of potential bias in supplement research. Both major trials were funded by companies with commercial interests in Magtein®. The trials themselves are methodologically sound (randomised, double-blind, placebo-controlled), which limits but does not eliminate bias risk. Holding the findings to a higher standard of replication by independent research groups is a reasonable approach before drawing firm conclusions.
References
[1] Lopresti AL, et al. "The effects of magnesium L-threonate (Magtein®) on cognitive performance and sleep quality in adults: a randomised, double-blind, placebo-controlled trial." Frontiers in Nutrition. 2026. DOI: 10.3389/fnut.2025.1729164
[2] Hausenblas HA, et al. "Magnesium-L-threonate improves sleep quality and daytime functioning in adults with self-reported sleep problems: A randomized controlled trial." Sleep Medicine: X. 2024. DOI: 10.1016/j.sleepx.2024.100121
[3] Zhang C, et al. "A Magtein®, Magnesium L-Threonate, -Based Formula Improves Brain Cognitive Functions in Healthy Chinese Adults." Nutrients. 2022. DOI: 10.3390/nu14245235
[4] Chen H, et al. "Magnesium and Cognitive Health in Adults: A Systematic Review and Meta-Analysis." Advances in Nutrition. 2024. DOI: 10.1016/j.advnut.2024.100272
[5] Mah J, Pitre T. "Oral magnesium supplementation for insomnia in older adults: a Systematic Review & Meta-Analysis." BMC Complementary Medicine and Therapies. 2021. DOI: 10.1186/s12906-021-03297-z
[6] Slutsky I, et al. "Enhancement of learning and memory by elevating brain magnesium." Neuron. 2010. DOI: 10.1016/j.neuron.2009.12.026
[7] Wroolie TE, et al. "An 8-week open label trial of l-Threonic Acid Magnesium Salt in patients with mild to moderate dementia." Personalized Medicine in Psychiatry. 2017. DOI: 10.1016/j.pmip.2017.07.001
This content is for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any supplement or making changes to your health regimen.
